InvestorsHub Logo
Followers 427
Posts 26168
Boards Moderated 4
Alias Born 09/26/2009

Re: None

Thursday, 12/29/2022 8:02:15 AM

Thursday, December 29, 2022 8:02:15 AM

Post# of 1602
Looks like approval is coming soon, why else would they want to develop the label?

In the AGL, OND directs the FDA’s Division of Cardiology and Nephrology (“DCN”) to work with the Company to develop an
appropriate label. The Company believes that a label could reflect an indication for patients whose hyperphosphatemia is insufficiently managed on binder therapy.

Well that didn't go the way I expected

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARDX News